Status:
COMPLETED
Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapy
Lead Sponsor:
CHA University
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
19+ years
Brief Summary
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths worldwide, and HCC is more frequently observed in Asia, including South Korea. As HCC is often accompanied by chr...
Detailed Description
to establish multi-omics data and discover biomarkers highly associated with treatment response in HCC patients
Eligibility Criteria
Inclusion
- Those above the age of 20 who understand the purpose of the study and agree to participate in the collection of samples during the study.
- Patients who have been diagnosed with unresectable advanced HCC through imaging, histological, or cytological tests.
- Patients who underwent an NGS test with advanced HCC tissues
- Patients who are scheduled to receive systemic treatment
- Patients with measurable lesions based on RECIST v1.1
- ECOG performance status 0 or 1
- Patients with a life expectancy of at least three months
Exclusion
- Patients who have systemic conditions accompanied by instability of vital signs, such as infections or organ failure
- Those with mental/neurological conditions or dementia who have difficulties understanding and completing the consent form
- Those who are assessed as not suitable for this study, at the discretion of the researcher
Key Trial Info
Start Date :
December 20 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
166 Patients enrolled
Trial Details
Trial ID
NCT05197504
Start Date
December 20 2021
End Date
December 31 2023
Last Update
September 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHA Bundang Medical Center
Seongnam-si, Gyeonggi-do, South Korea, 13496